{"id":301,"date":"2020-06-23T06:37:16","date_gmt":"2020-06-23T06:37:16","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=301"},"modified":"2020-06-23T06:38:24","modified_gmt":"2020-06-23T06:38:24","slug":"23-june-2020-dexamethasone-reduced-deaths-by-one-third-in-patients-receiving-invasive-mechanical-ventilation","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/23-june-2020-dexamethasone-reduced-deaths-by-one-third-in-patients-receiving-invasive-mechanical-ventilation\/","title":{"rendered":"(23 June 2020) Dexamethasone- reduced deaths by one-third in patients receiving invasive mechanical ventilation"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.22.20137273v1<\/p>\n<p class=\"\">Reports from&nbsp; the preliminary results of RECOVERY trial [The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (<a class=\"external-ref external-ref-type-clintrialgov\" href=\"https:\/\/www.medrxiv.org\/lookup\/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT04381936&amp;atom=%2Fmedrxiv%2Fearly%2F2020%2F06%2F22%2F2020.06.22.20137273.atom\">NCT04381936<\/a>)]for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone are presented. The primary outcome was 28-day mortality. 2104 patients randomly allocated to receive dexamethasone were compared with 4321 patients concurrently allocated to usual care. Overall, 454 (21.6%) patients allocated dexamethasone and 1065 (24.6%) patients allocated usual care died within 28 days (age-adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; P&lt;0.001). Dexamethasone reduced deaths by one-third in patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; p&lt;0.001), by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; p=0.002), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs. 13.2%, RR 1.22 [95% CI 0.93 to 1.61]; p=0.14). In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report https:\/\/www.medrxiv.org\/content\/10.1101\/2020.06.22.20137273v1 Reports from&nbsp; the preliminary results of RECOVERY trial [The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936)]for the comparison of dexamethasone 6 mg given once daily for&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/23-june-2020-dexamethasone-reduced-deaths-by-one-third-in-patients-receiving-invasive-mechanical-ventilation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(23 June 2020) Dexamethasone- reduced deaths by one-third in patients receiving invasive mechanical ventilation&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4],"tags":[68],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/301"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=301"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/301\/revisions"}],"predecessor-version":[{"id":302,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/301\/revisions\/302"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}